FOLH1 and neoplasm: As data with [177Lu]Lu-PSMA-617 in mCRPC patients show, the ability to deliver a higher radiation dose to the tumour results in greater efficacy [7, 22], and as our previous data show, [177Lu]Lu-rhPSMA-10.1 delivers a significantly higher radiation dose to the tumour compared with [177Lu]Lu-PSMA-I&T [6], potentially overcoming primary or acquired radiation resistance and thus enabling a response to [177Lu]Lu-rhPSMA-10.1 after progression on [177Lu]Lu-PSMA-I&T.